Novel chemoradiosensitizers for cancer therapy

Anticancer Research

Volumn 30, Issue 9, 2010, Pages 3675-3682

  Page, Paul ^a   Yang, Li Xi ^a,b  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b ST MARY S MEDICAL CENTER   (United States)

Author keywords

Chemoradiosensitizers; Chemotherapy; New radiosensitizing drugs; Novel agents; Radiotherapy; Review

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BELOTECAN; BEVACIZUMAB; BSI 201; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; EXATECAN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GPI 15427; HISTONE DEACETYLASE INHIBITOR; IRINOTECAN; KARENITECAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; OXALIPLATIN; RUBITECAN; TEMOZOLOMIDE; TLC 388; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT; RADIOSENSITIZING AGENT;

ADJUVANT THERAPY; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BRAIN METASTASIS; BRAIN TUMOR; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DEHYDRATION; DIGESTIVE SYSTEM CANCER; DISEASE FREE SURVIVAL; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; LEUKOPENIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RADIOSENSITIZATION; RECTUM CANCER; REVIEW; RHABDOMYOSARCOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; WEAKNESS; ANIMAL; CLINICAL TRIAL (TOPIC); MULTIMODALITY CANCER THERAPY; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; NEOPLASMS; RADIATION-SENSITIZING AGENTS;

EID: 77958610266     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Katz D, Ito E and Liu FF: On the path to seeking novel radiosensitizers. Int J Radiat Oncol Biol Phys 73: 988-996, 2009.
2. Steel GG and Peckham MJ: Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5: 85-91, 1979.
3. Bentzen SM, Harari PM and Bernier J: Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions. Nat Clin Pract Oncol 4: 172-180, 2007.
4. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp.
5. Adelstein DJ, Li Y, Adams GL, Wagner H, Jr., Kish JA, Ensley JF, Schuller DE and Forastiere AA: An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21: 92-98, 2003.
6. Cho LC and Choy H: Topoisomerase I inhibitors in the combined-modality therapy of lung cancer. Oncology (Williston Park) 18: 29-39, 2004.
7. Grabenbauer GG, Gerber KD, Ganslandt O, Richter A, Klautke G, Birkmann J and Meyer M: Effects of concurrent topotecan and radiation on 6-month progression-free survival in the primary treatment of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 75: 164-169, 2009.
8. Glynne-Jones R, Falk S, Maughan TS, Meadows HM and Sebag-Montefiore D: A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study. Br J Cancer 96: 551-558, 2007. (Pubitemid 46303528)
9. Fabbro M, Gladieff L, Guichard F, El Demery M, Dalenc F, Kerr C et al: Phase I study of irinotecan and cisplatin in combination with pelvic radiotherapy in the treatment of locally advanced cervical cancer: A GINECO trial. Gynecol Oncol 117: 276-280, 2010.
10. Kalofonos HP, Bamias A, Koutras A, Papakostas P, Basdanis G, Samantas E et al: A randomised phase III trial of adjuvant radio-chemotherapy comparing irinotecan, 5FU and leucovorin to 5FU and leucovorin in patients with rectal cancer: a Hellenic Cooperative Oncology Group Study. Eur J Cancer 44: 1693-1700, 2008.
11. Neuhaus T, Ko Y, Muller RP, Grabenbauer GG, Hedde JP, Schueller H et al: A phase III trial of topotecan and whole brain radiation therapy for patients with CNS metastases due to lung cancer. Br J Cancer 100: 291-297, 2009.
12. Wong SJ WK, Meropol NJ, Kachnic LA, Rashid A, Watson JC, Mitchell EP, Pollock J, Lee RJ, Willett CG: RTOG 0247: A randomized phase II study of neoadjuvant capecitabine and irinotecan versus capecitabine and oxaliplatin with concurrent radiation therapy for locally advanced rectal cancer. J Clin Oncol 26: Abstract 4021, 2008.
13. www.clinicaltrials.gov.
14. NCT00354835.
15. Teicher BA: Next generation topoisomerase I inhibitors: Rationale and biomarker strategies. Biochem Pharmacol 75: 1262-1271, 2008.
16. Legarza K and Yang LX: Novel camptothecin derivatives. In Vivo 19: 283-292, 2005.
17. Lee DH, Kim SW, Suh C, Lee JS, Ahn JS, Ahn MJ et al: Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer. Cancer 116: 132-136, 2010.
18. Kim HS, Kang SB, Seo SS, Han SS, Kim JW, Park NH et al: Phase I/IIa study of combination chemotherapy with CKD-602 and cisplatin in patients with recurrent epithelial ovarian cancer. Ann N Y Acad Sci 1171: 627-634, 2009.
19. Lee HP, Seo SS, Ryu SY, Kim JH, Bang YJ, Park SY et al: Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer. Gynecol Oncol 109: 359-363, 2008.
20. Scott LC, Yao JC, Benson AB, 3rd, Thomas AL, Falk S, Mena RR et al: A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemother Pharmacol 63: 363-370, 2009.
21. Miller AA, Herndon JE, 2nd, Gu L and Green MR: Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004). Lung Cancer 48: 399-407, 2005.
22. Abou-Alfa GK, Letoumeau R, Harker G, Modiano M, Hurwitz H, Tchekmedyian NS et al: Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 24: 4441-4447, 2006.
23. Cheverton P FH, Andras C, Salek T, Geddes C, Bodoky G, Valle J and Humblet Y. Phase III results of exatecan (DX-8951f) versus gemcitabine (Gem) in chemotherapy-naive patients with advanced pancreatic cancer (APC). J Clin Oncol 22: Abstract 4005, 2004.
24. NCT00477282.
25. NCT00826644.
26. Tedesco KL, Berlin J, Rothenberg M, Choy H, Wyman K, Scott Pearson A et al: A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas. Radiother Oncol 76: 54-58, 2005.
27. Gounaris I, Zaki K and Corrie P: Options for the treatment of gemcitabine-resistant advanced pancreatic cancer. J Pancreas (Online) 11: 113-123, 2010.
28. Huang G, Wang H and Yang LX: Enhancement of radiation-induced DNA damage and inhibition of its repair by a novel camptothecin analog. Anticancer Res 30: 937-944, 2010.
29. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567-578, 2006.
30. Comen EA and Robson M: Inhibition of poly(ADP)-ribose polymerase as a therapeutic strategy for breast cancer. Oncology (Williston Park) 24: 55-62, 2010.
31. Drew Y and Plummer R: The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer. Curr Opin Obstet Gynecol 22: 67-71, 2010.
32. Russo AL, Kwon HC, Burgan WE, Carter D, Beam K, Weizheng X et al: In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016. Clin Cancer Res 15: 607-612, 2009.
33. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M et al: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123-134, 2009.
34. Dungey FA, Loser DA and Chalmers AJ: Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. Int J Radiat Oncol Biol Phys 72: 1188-1197, 2008.
35. Khan K, Araki K, Wang D, Li G, Li X, Zhang J et al: Head and neck cancer radiosensitization by the novel poly(ADP-ribose) polymerase inhibitor GPI-15427. Head Neck 32: 381-391, 2010.
36. NCT00938652.
37. NCT01082549.
38. NCT00687765.
39. Shabason JE, Tofilon P and Camphausen K: HDAC inhibitors in cancer care. Oncology (Williston Park) 24: 180-185, 2010.
40. Ma X, Ezzeldin HH and Diasio RB: Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 69: 1911-1934, 2009.
41. Camphausen K and Tofilon PJ. Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J Clin Oncol 25: 4051-4056, 2007. (Pubitemid 47492949)
42. Ree AH, Dueland S, Folkvord S, Hole KH, Seierstad T, Johansen M et al: Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. Lancet Oncol 11: 459-464, 2010.
43. Taldone T, Gozman A, Maharaj R and Chiosis G: Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol 8: 370-374, 2008.
44. Ramanathan RK, Egorin MJ, Erlichman C, Remick SC, Ramalingam SS, Naret C et al: Phase I pharmacokinetic and pharmacodynamic study of 17- dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors. J Clin Oncol 28: 1520-1526, 2010.
45. Camphausen K and Tofilon PJ: Inhibition of Hsp90: a multitarget approach to radiosensitization. Clin Cancer Res 13: 4326-4330, 2007. (Pubitemid 47219695)
46. Kabakov AE, Kudryavtsev VA and Gabai VL: Hsp90 inhibitors as promising agents for radiotherapy. J Mol Med 88: 241-247, 2010.
47. Sauvageot CM, Weatherbee JL, Kesari S, Winters SE, Barnes J, Dellagatta J et al: Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. Neuro Oncol 11: 109-121, 2009.
48. Koll TT, Feis SS, Wright MH, Teniola MM, Richardson MM, Robles AI et al: HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair. Mol Cancer Ther 7: 1985-92, 2008.
49. Dote H, Cerna D, Burgan WE, Camphausen K and Tofilon PJ: ErbB3 expression predicts tumor cell radiosensitization induced by Hsp90 inhibition. Cancer Res 65: 6967-6975, 2005. (Pubitemid 41060737)
50. Dote H, Burgan WE, Camphausen K and Tofilon PJ: Inhibition of Hsp90 compromises the DNA damage response to radiation. Cancer Res 66: 9211-9220, 2006. (Pubitemid 44521142)
51. Ronnen EA, Kondagunta GV, Ishill N, Sweeney SM, Deluca JK, Schwartz L et al: A phase II trial of 17-(allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest New Drugs 24: 543-546, 2006. (Pubitemid 44273031)
52. Solit DB, Osman I, Polsky D, Panageas KS, Daud A, Goydos JS et al: Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res 14: 8302-8307, 2008.
53. Badros AZ RP, Albitar M, Jagannath S, Tarantolo S, Wolf JL, Messina M, Berman D and Anderson KC: Tanespimycin + bortezomib in relapsed/refractory myeloma patients: results from the study. 51st American Society of Hematology Annual Meeting Online Program and Abstracts: Abstract 1871, 2009.
54. NCT00708292.
55. NCT01063907.
56. NCT00577889.
57. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.